Guangzhou Zaiji Medical Technology Co., Ltd.

Primary objectives: 1) Phase 1: To evaluate the safety and tolerability of MAX-40279 combined with venetoclax tablets + azacitidine regimen (abbreviated as "VA") in the treatment of newly diagnosed acute myeloid leukemia (AML) patients who are not suitable for intensive chemotherapy, and determine the recommended dose (RP2D). 2) Phase 2: To evaluate the composite complete remission rate (CRc) of MAX-40279 combined with VA in the treatment of newly diagnosed AML who are not suitable for intensive chemotherapy. Secondary objectives: 1) To evaluate other efficacy indicators of MAX-40279 combined with VA in the treatment of newly diagnosed AML who are not suitable for intensive chemotherapy. 2) To evaluate the pharmacokinetic (PK) characteristics of MAX-40279 combined with VA. Exploratory objectives: 1) To explore and analyze potential biomarkers associated with efficacy.

1) To evaluate the safety and tolerability, pharmacokinetics, and recommended combined dose (RP2D) of MAX-10181 combined with temozolomide (TMZ) in patients with recurrent/progressive high-grade glioma (HGG). 2) To evaluate the preliminary efficacy of MAX-10181 combined with TMZ in patients with newly diagnosed glioma.

Primary objectives: 1) Phase I: Evaluate the tolerability and safety of MAX-10181 combined with capecitabine in patients with advanced/metastatic solid tumors, and determine the recommended dose (RP2D) of MAX-10181 combined with capecitabine in different solid tumors. 2) Phase II: Evaluate the preliminary efficacy of MAX-10181 combined with capecitabine in patients with advanced/metastatic solid tumors. Secondary objectives: 1) Evaluate the pharmacokinetic (PK) characteristics of MAX-10181 combined with capecitabine in the treatment of patients with advanced/metastatic solid tumors. 2) Retrospectively analyze the relationship between relevant biomarkers and the anti-tumor effect of MAX-10181 combined with capecitabine.